



ALLA MAGNIFICA RETTRICE  
DELL'UNIVERSITA' DEGLI STUDI DI MILANO

COD. ID: 6981

Il sottoscritto chiede di essere ammesso a partecipare alla selezione pubblica, per titoli ed esami, per il conferimento di un assegno di ricerca presso il Dipartimento di Scienze Cliniche e di Comunità

Responsabile scientifico: Prof.ssa Irene MOTTA

[Rayan BOU-FAKHREDIN]

## CURRICULUM VITAE

### INFORMAZIONI PERSONALI

Cognome	BOU-FAKHREDIN
Nome	RAYAN

### OCCUPAZIONE ATTUALE

Incarico	Struttura
Università degli Studi di Milano	PhD Student-Translational Medicine

### ISTRUZIONE E FORMAZIONE

Titolo	Corso di studi	Università	anno conseguimento titolo
Laurea Magistrale o equivalente	Biology	American University of Beirut (AUB)	2015
Specializzazione			
Dottorato Di Ricerca	Translational Medicine	Università degli Studi di Milano	Expected: January 2025
Master	Physiology	American University of Beirut (AUB)	2020
Diploma Di Specializzazione Medica			
Diploma Di Specializzazione Europea			
Altro			

### ISCRIZIONE AD ORDINI PROFESSIONALI

Data iscrizione	Ordine	Città



## LINGUE STRANIERE CONOSCIUTE

lingue	livello di conoscenza
English	Native
Arabic	Native
Spanish	Native
Italian	Intermediate

## PREMI, RICONOSCIMENTI E BORSE DI STUDIO (2021-2024)

anno	Descrizione premio
November 2023	Inducted to Sigma Xi, The Scientific Research Honor Society, as a full member "in recognition of my scholarly achievements and contributions to the advancement of knowledge in my field of study"
November 2021	Placed and recognized by Expertscape's PubMed-based algorithm among the top 1% of expert scholars writing about Thalassemia over the past 10 years.

## ATTIVITÀ DI FORMAZIONE O DI RICERCA

**descrizione dell'attività: Visiting Research Scholar**-Department of Hematology, Children's Hospital of Philadelphia (CHOP) and the University of Pennsylvania (UPenn), Philadelphia, PA, USA (January 2023-July 2023)

## ATTIVITÀ PROGETTUALE

Anno	Progetto

## TITOLARITÀ DI BREVETTI

Brevetto

## CONGRESSI, CONVEGNI E SEMINARI (2021-2024)

Data	Titolo	Sede



October 02-05, 2024	19th Annual Academy of Sickle Cell and Thalassaemia Conference (ASCAT)	London, UK
September 30-October 01, 2024	MEETING DEL CLUB DEL GLOBULO ROSSO 2024	Naples, Italy
September 19-20, 2024	Anemia Forum	Amsterdam, Netherlands
June 13-16, 2024	29th European Hematology Association (EHA) Congress	Madrid, Spain
March 2-3, 2024	2024 Highlights of ASH in the Mediterranean	Dubai, UAE
June 25-30, 2023	72nd Lindau Nobel Laureate Meeting (Physiology and Medicine-	Lindau, Germany
June 8-12, 2022	European Hematology Association 2022 Annual Congress	Vienna, Austria
April 7-11, 2022	24th Meeting of the European Red Cell Society (ERCS)	Villa Cagnola, Gazzada Schianno - Italy
December 2021-March 2022	1st Sickle Cell Disease Academy-MENA Region	Virtual
November 19-21, 2021	15th International Conference on Thalassemia and other Hemoglobinopathies-Thalassemia International Federation	Virtual
September 24-26, 2021	Inborn Errors Working Party Annual Conference 2021- European Society for Blood and Marrow Transplantation (EBMT)	Milan, Italy

## PUBBLICAZIONI (2016-2024)

<b>Libri</b>
<b>Bou-Fakhredin R, Taher AT.</b> <i>Chapter 18: Novel and Emerging Therapies.</i> Guidelines for the Management of Transfusion Dependent Thalassaemia (TDT). 4th Edition. Nicosia, Cyprus: Thalassemia International Federation. 2021.

<b>Articoli su riviste</b>
----------------------------



1. **Bou Fakhredin R**, Cappellini MD, Taher A, De Franceschi L. Thrombosis in Hemoglobinopathies: Decoding the Thrombotic Threat. *Am J Hematol*. 2024 Oct 14. doi: 10.1002/ajh.27500. Online ahead of print.
2. Panzieri DL, Consonni D, Scaramellini N, Ausenda G, Granata F, Caponio N, Duca L, Leoni S, Elli S, Ferraresi M, Bolis V, Curcio C, Irrera MA, Maira D, Graziadei G, Cassinerio E, Cappellini MD, **Bou-Fakhredin R**, Brancaloni V, Motta I. Real-world efficacy and safety of luspatercept and predictive factors of response in patients with transfusion-dependent  $\beta$ -thalassemia. *Am J Hematol*. 2024 Sep 12. doi: 10.1002/ajh.27474. Online ahead of print.
3. Iolascon A, Andolfo I, Russo R, Sanchez M, Busti F, Swinkels D, Aguilar Martinez P, **Bou-Fakhredin R**, Muckenthaler MU, Unal S, Porto G, Ganz T, Kattamis A, De Franceschi L, Cappellini MD, Munro MG, Taher A; from EHA-SWG Red Cell and Iron. Recommendations for diagnosis, treatment, and prevention of iron deficiency and iron deficiency anemia. *Hemasphere*. 2024 Jul 15;8(7):e108.
4. Granata F, **Bou-Fakhredin R**, Cappellini MD, Motta I. Step out of the shadows: a call for action for rare diseases. *Lancet Haematol*. 2024 Jun;11(6):e403.
5. Bizri M, Koleilat R, Akiki N, Dergham R, Mihailescu AM, **Bou-Fakhredin R**, Musallam KM, Taher AT. Quality of life, mood disorders, and cognitive impairment in adults with  $\beta$ -thalassemia. *Blood Rev*. 2024 May;65:101181.
6. Leoni S, **Bou-Fakhredin R**, Granata F, Cassinerio E, Maggioni M, Fracanzani AL, Cappellini MD, Motta I. Acute liver injury after SARS-CoV-2 vaccination and luspatercept administration in a patient with  $\beta$ -thalassemia. *Ann Hematol*. 2024 Mar;103(3):1025-1026.
7. Njeim R, Naouss B, **Bou-Fakhredin R**, Haddad A, Taher A. Unmet Needs in  $\beta$ -thalassemia and the Evolving Treatment Landscape. *Transfus Clin Biol*. 2024 Feb;31(1):48-55.
8. Hodroj MH, Akiki N, **Bou-Fakhredin R**, Taher AT. Beta-thalassemia: is cure still a dream? *Minerva Med*. 2023 Dec;114(6):850-860.
9. **Bou-Fakhredin R**, Kuo KHM, Taher AT. Emerging Therapies in  $\beta$ -Thalassemia. *Hematol Oncol Clin North Am*. 2023 Apr;37(2):449-462.
10. **Bou-Fakhredin R**, Motta I, Cappellini MD, Taher AT. Clinical Complications and Their Management. *Hematol Oncol Clin North Am*. 2023 Apr;37(2):365-378.
11. **Bou-Fakhredin R**, Rivella S, Cappellini MD, Taher AT. Pathogenic Mechanisms in Thalassemia I: Ineffective Erythropoiesis and Hypercoagulability. *Hematol Oncol Clin North Am*. 2023 Apr;37(2):341-351.
12. Akiki N, Hodroj MH, **Bou-Fakhredin R**, Matli K, Taher AT. Cardiovascular Complications in  $\beta$ -Thalassemia: Getting to the Heart of It. *Thalassemia Reports*. 2023 Jan 30;13(1):38-50.



13. Moukalled NM, **Bou-Fakhredin R**, Taher AT. Pregnancy and sickle cell disease: an overview of complications and suggested perinatal care. *Expert Rev Hematol*. 2022 Dec;15(12):1055-1061.
14. **Bou-Fakhredin R**, De Franceschi L, Motta I, Cappellini MD, Taher AT. Pharmacological Induction of Fetal Hemoglobin in  $\beta$ -Thalassemia and Sickle Cell Disease: An Updated Perspective. *Pharmaceuticals (Basel)*. 2022 Jun 16;15(6):753.
15. **Bou-Fakhredin R**, De Franceschi L, Motta I, Eid AA, Taher AT, Cappellini MD. Redox Balance in  $\beta$ -Thalassemia and Sickle Cell Disease: A Love and Hate Relationship. *Antioxidants (Basel)*. 2022 May 13;11(5):967.
16. Jarrah K, Al Mahmasani L, Atoui A, **Bou-Fakhredin R**, Taher AT. Manifestation of paroxysmal nocturnal hemoglobinuria after COVID-19 mRNA vaccination. *Blood Cells Mol Dis*. 2022 Mar;93:102641.
17. Sabbagh S, Jarrah K, **Bou-Fakhredin R**, Saadeh D, Taher AT. Anhidrosis associated with long-term use of hydroxyurea in a patient with myeloproliferative neoplasm. *Ann Hematol*. 2022 Jul;101(7):1595-1596.
18. Atoui A, Jarrah K, Al Mahmasani L, **Bou-Fakhredin R**, Taher AT. Deep venous thrombosis and pulmonary embolism after COVID-19 mRNA vaccination. *Ann Hematol*. 2022 May;101(5):1111-1113.
19. **Bou-Fakhredin R**, Motta I, Cappellini MD. Advancing the care of  $\beta$ -thalassaemia patients with novel therapies. *Blood Transfus*. 2022 Jan;20(1):78-88.
20. Taher AT, **Bou-Fakhredin R**, Kattamis A, Viprakasit V, Cappellini MD. Improving outcomes and quality of life for patients with transfusion-dependent  $\beta$ -thalassemia: recommendations for best clinical practice and the use of novel treatment strategies. *Expert Rev Hematol*. 2021 Oct;14(10):897-909.
21. Musallam KM, **Bou-Fakhredin R\***, Cappellini MD, Taher AT. 2021 Update on Clinical Trials in  $\beta$ -Thalassemia. *Am J Hematol*. 2021 Nov 1;96(11):1518-1531.
22. Abdulhai F, Jaffa MA, Elias J, Zakka P, Hotait M, **Bou-Fakhredin R**, Arnaout S, Taher AT, Refaat MM. Digital thermography and vascular involvement in  $\beta$ -thalassemia intermedia. *Ann Hematol*. 2021 Oct;100(10):2471-2477.
23. **Bou-Fakhredin R**, Daadaa H, Koussa S, Abou Nasr T, Noun P, Taher AT. SARS-CoV-2 infection in patients with  $\beta$ -thalassemia: Experience from Lebanon. *Am J Hematol*. 2021 Aug 1;96(8):E285-E288.
24. Matar CF, **Bou-Fakhredin R\***, Russo R, Andolfo I, Iolascon A, Taher AT. Recommendations for Pregnancy in Fanconi Anemia. *Expert Opin Biol Ther*. 2021 Nov;21(11):1403-1409.
25. **Bou-Fakhredin R**, Dia B, Ghadieh HE, Rivella S, Cappellini MD, Eid AA, Taher AT. CYP450 Mediates Reactive Oxygen Species Production in a Mouse Model of  $\beta$ -Thalassemia through an Increase in 20-HETE Activity. *Int J Mol Sci*. 2021 Jan 23;22(3):1106.



26. Noun P, Ibrahim A, Hodroj MH, **Bou-Fakhredin R**, Taher AT. COVID-19 in benign hematology: emerging challenges and special considerations for healthcare professionals. *Expert Rev Hematol*. 2020 Oct;13(10):1081-1092.
27. Taher AT, Iolascon A, Matar CF, **Bou-Fakhredin R**, de Franceschi L, Cappellini MD, Barcellini W, Russo R, Andolfo I, Tyan P, Gulbis B, Aydinok Y, Anagnou NP, Bencaiova GA, Tamary H, Martinez PA, Forni G, Vindigni R on behalf of the EHA Scientific Working Group on "Red Cells and Iron". Recommendations for Pregnancy in Rare inherited Anemias. *HemaSphere* (2020) 4:4(e446).
28. **Bou-Fakhredin R**, Ghanem NN, Kreidieh F, Tabbikha R, Daadaa H, Ajouz J, Koussa S, Taher AT. A Report on the Education, Employment and Marital Status of Thalassemia Patients from a Tertiary Care Center in the Middle East. *Hemoglobin*. 2020 Jul;44(4):278-283.
29. Saliba AN, Atoui A, Labban M, Hamade H, **Bou-Fakhredin R**, Mufarrij A, Taher AT. Thalassemia in the Emergency Department: Special Considerations for a Rare Disease. *Ann Hematol*. 2020 Sep;99(9):1967-1977.
30. Motta I, **Bou-Fakhredin R**, Taher AT, Cappellini MD. Beta Thalassemia: New Therapeutic Options Beyond Transfusion and Iron Chelation. *Drugs*. 2020 Jul;80(11):1053-1063.
31. Taher AT, **Bou-Fakhredin R**, Kreidieh F, Motta I, De Franceschi L, Cappellini MD. Care of Patients with Hemoglobin Disorders during the COVID-19 Pandemic: An Overview of Recommendations. *Am J Hematol*. 2020 Aug;95(8):E208-E210
32. **Bou-Fakhredin R**, Tabbikha R, Daadaa H, Taher AT. Emerging therapies in  $\beta$ -Thalassemia: towards a new era in management. *Expert Opin Emerg Drugs*. 2020 Jun;25(2):113-122.
33. Al Mahmasani L, Finianos A, **Bou-Fakhredin R**, Elias J, Taher A. Acquired hemophilia A: when an overlooked autoimmune disorder causes significant bleeding. *Expert Opinion on Orphan Drugs*. 2020;8(2-3):79-89.
34. El Merhi F, **Bou-Fakhredin R**, El Ashkar B, Ghieh D, Ghosn Y, Saade C. State of the art of coronary computed tomography angiography. *Radiography*. 2020 May;26(2):174-182
35. Hodroj MH, **Bou-Fakhredin R**, Nour-Eldine W, Nouredine HA, Nouredine MHA, Taher AT. Thalassemia and malignancy: An emerging concern? *Blood Rev*. 2019;37:100585.
36. Saade C, **Bou Fakhredin R**, El Achkar B, Ghieh D, Mayat A, Abchee A, Refaat M, Ismail H, El-Rayess H, Karout L, El Merhi F. Coronary Artery Anomalies and Associated Radiologic Findings. *J Comput Assist Tomogr*. 2019 Jul/Aug;43(4):572-583.
37. Moukalled NM, **Bou-Fakhredin R**, Taher AT. Deferasirox: Over a Decade of Experience in Thalassemia. *Mediterr J Hematol Infect Dis*. 2018 Nov 1;10(1):e2018066.
38. Saade C, **Bou-Fakhredin R**, Yousem DM, Asmar K, Naffaa L, El-Merhi F. Gadolinium and Multiple Sclerosis: Vessels, Barriers of the Brain, and Glymphatics. *AJNR Am J Neuroradiol*. 2018 Dec;39(12):2168-2176.
39. Moukhadder HM, Roumi JE, **Bou-Fakhredin R**, Taher AT. Hepatocellular Carcinoma in a  $\beta$ -Thalassemia Intermedia Patient: Yet Another Case in the Expanding Epidemic. *Hemoglobin*. 2018 Jan;42(1):58-60.





40. Taher AT, Cappellini MD, **Bou-Fakhredin R**, Coriu D, Musallam KM. Hypercoagulability and Vascular Disease. *Hematol Oncol Clin North Am*. 2018 Apr;32(2):237-245
41. Sleiman J, Tarhini A, **Bou-Fakhredin R**, Saliba AN, Cappellini MD, Taher AT. Non-Transfusion-Dependent Thalassemia: An Update on Complications and Management. *Int J Mol Sci*. 2018 Jan 8;19(1). pii: E182.
42. **Bou-Fakhredin R**, Bazarbachi AH, Chaya B, Sleiman J, Cappellini MD, Taher AT. Iron Overload and Chelation Therapy in Non-Transfusion Dependent Thalassemia. *Int J Mol Sci*. 2017 Dec 20;18(12). pii: E2778.
43. Youssry I, Abdel-Salam A, Ismail R, **Bou-Fakhredin R**, Mohamed Samy R, Ezz El-Deen F, Taher AT. Enhancing Effect of Hydroxyurea on Hb F in Sickle Cell Disease: Ten-Year Egyptian Experience. *Hemoglobin*. 2017 Jul - Nov;41(4-6):267-273.
44. Saliba AN, Moukhadder HM, Harb A, Beydoun H, **Bou-Fakhredin R**, Taher AT. Causes of Hospital Admission in  $\beta$ -Thalassemia (CHAT) in Lebanon from 1995 to 2015: A pilot retrospective study from a tertiary care center. *Am J Hematol*. 2017 Dec;92(12):E652-E653
45. **Bou-Fakhredin R**, Halawi R, Roumi J, Taher A. Insights into the Diagnosis and Management of Iron Deficiency in Inflammatory Bowel Disease. *Expert Rev Hematol*. 2017 Sep;10(9):801-808
46. Ben Salah N, **Bou-Fakhredin R**, Mellouli F, Taher AT. Revisiting beta thalassemia intermedia: past, present, and future prospects. *Hematology*. 2017 Dec;22(10):607-616
47. Youssry I, Soliman N, Ghamrawy M, Samy RM, Nasr A, Abdel Mohsen M, ElShahaat M, **Bou Fakhredin R**, Taher A. Circulating microparticles and the risk of thromboembolic events in Egyptian beta thalassemia patients. *Ann Hematol*. 2017 Apr;96(4):597-603.
48. **Bou Fakhredin R**, Saade C, Kerek R, El-Jamal L, Khoury SJ, El-Merhi F. Imaging in multiple sclerosis: A new spin on lesions. *Journal of Medical Imaging and Radiation Oncology*. 2016 Oct; 60(5):577-86.

## Atti di convegni (Conference Abstracts) (2016-2024)

1. **R. Bou-Fakhredin**, M. Longo, M. Meroni, S. Alkhansa, A. Slika, S. Al Moussawi, B. Dia, A.A. Eid, P. Dongiovanni, M.D. Cappellini, A. Taher, I. Motta, S. Rivella. Inhibition of 20-hete induced oxidative stress ameliorates liver injury in a mouse model of  $\beta$ eta thalassemia. Poster Presentation. 19th Annual Academy of Sickel Cell and Thalassemia Conference (ASCAT), October 02-05, 2024, London, UK.
2. **R. Bou-Fakhredin**, M. Longo, M. Meroni, S. Alkhansa, A. Slika, S. Al Moussawi, B. Dia, A.A. Eid, P. Dongiovanni, M.D. Cappellini, A. Taher, I. Motta, S. Rivella. Inhibition of 20-hete induced oxidative stress ameliorates liver injury in a mouse model of  $\beta$ eta thalassemia. Oral Communication - MEETING DEL CLUB DEL GLOBULO ROSSO 2024, September 30-October 01, 2024, Naples. Italy.



3. Daniele Lello Panzieri, Guido Ausenda, Natalia Scaramellini, Dario Consonni, Francesca Granata, Nancy Caponio, Lorena Duca, Simona Leoni, Silvia Elli, Marta Ferraresi, Elena Cassinerio, Greta Rossi, Cristina Curcio, Milena Agata Irrera, Elena Trombetta, Marta Tornese, Giovanna Graziadei, Maria Domenica Cappellini, **Rayan Bou-Fakhredin**, Valentina Brancaleoni, Irene Motta. Predicting and evaluating response to luspatercept in transfusion-dependent  $\beta$ -thalassemia: new insight from a real-life experience. 29th European Hematology Association (EHA) Congress-June 13-16, 2024-Madrid, Spain. (Poster Presentation)
4. Ahmad Machmouchi, **Rayan Bou-Fakhredin\***, Joseph Klim, Layal Sharrouf, Maya Rahme, Maya Charafeddine, Ali Taher, Ghada El-Hajj Fuleihan. Does Iron Overload in Patients with Thalassemia Affect Bone Mineral Density Acquisition by Dual-Energy X-ray Absorptiometry and its Precision? 29th European Hematology Association (EHA) Congress-June 13-16, 2024-Madrid, Spain. (Poster Presentation)
5. **Bou-Fakhredin R\***, Eid AA, Taher A. Oxidative stress in Non-Transfusion Dependent Thalassemia: A Journey from NADPH oxidases to cytochrome P450. 15<sup>th</sup> Annual Sick Cell and Thalassemia and 1<sup>st</sup> EHA European Sick Cell Conference- October 26-31 2020-Virtual (Oral Presentation)
6. **Bou-Fakhredin R\***, Eid AA, Taher A. Oxidative stress in Non-Transfusion Dependent Thalassemia: A Journey from NADPH oxidases to cytochrome P450. Virtual Edition of the 25th EHA Annual Congress: "Unfolding the future!"-June 11-21, 2020 (E-poster Presentation)
7. **Bou-Fakhredin R\***, Eid AA, Taher A. Oxidative stress: a novel therapeutic target in non-transfusion dependent thalassemia (NTDT). EHA-SWG Scientific Meeting on Red Cell and Iron Metabolism Defects: From basic science to clinical case application-November 7-9 2019-Madrid, Spain (Oral Presentation)
8. **Bou-Fakhredin R\***, Eid AA, Taher A. Oxidative stress: a novel therapeutic target in non-transfusion dependent thalassemia (NTDT). International conference on Erythropoiesis control and ineffective erythropoiesis: from bench to bedside- March 15-17 2019-Budapest, Hungary.
9. A Marcon , J. Sleiman, A. Tarhini, G. Graziadei, **R. Bou-Fakhredin**, E. Cassinerio, A. Taher, M.D. Cappellini. Comparison of morbidities between non transfusion and transfusion dependent thalassemia patients older than 45 years. 23rd Congress of the European Hematology Association (EHA), June 14-17 2018, Stockholm, Sweden
10. Saliba AN, Moukhadder HM, Harb A, Beydoun H, **Bou-Fakhredin R\***, Taher AT. Causes of Hospital Admission in  $\beta$ -Thalassemia (CHAT) in Lebanon from 1995 to 2015: a pilot retrospective study from a tertiary care center. Thalassemia International Federation, 14<sup>th</sup> International Conference on Thalassemia and Other Hemoglobinopathies & 16<sup>th</sup> TIF Conference for patients and parents – Thessaloniki, Greece – November 17-19, 2017
11. Moukhadder HM, Baz P, Bejjani R, **Bou-Fakhredin R\***, Taher AT. Unusual Fluorescein Angiography and Spectral Domain-Optical Coherence Tomography Findings in Deferoxamine Retinopathy: A Case Report. Thalassemia International Federation, 14<sup>th</sup> International Conference on Thalassemia and Other Hemoglobinopathies & 16<sup>th</sup> TIF Conference for patients and parents – Thessaloniki, Greece – November 17-19, 2017
12. Roumi J, **Bou Fakhredin R**, Moukhadder HM, Beydoun H, Abou Nasr T, Koussa S, Taher AT. Efficacy of Three Iron-Chelating Agents in Thalassemia Patients from Our Practice. 2nd MEGMA Conference on Thalassaemia and Other Haemoglobinopathies, Thalassemia International Federation (TIF) – Amman, Jordan – November 11th-12th 2016.





13. Moukhadder HM, **Bou Fakhredin R**, Roumi J, Beydoun H, Abou Nasr T, Koussa S, Taher AT. Serum Ferritin Level as a Surrogate to Liver Iron Concentration and Cardiac T2\* for Determination of Hepatic and Cardiac Iron Overload in Patients with Thalassemia Major. 2nd MEGMA Conference on Thalassaemia and Other Haemoglobinopathies, Thalassemia International Federation (TIF) – Amman, Jordan – November 11th-12th 2016.
14. Moukhadder HM, Roumi J, **Bou Fakhredin R**, Beydoun H, Abou Nasr T, Koussa S, Taher AT. Determination of Cardiac Function by Serum Ferritin Level, Cardiac T2\*, and Liver Iron Concentration in Patients with Thalassemia Major. 2nd MEGMA Conference on Thalassaemia and Other Haemoglobinopathies, Thalassemia International Federation (TIF) – Amman, Jordan – November 11th-12th 2016.
15. **Bou Fakhredin R\***, Roumi J, Ajouz J, Moukhadder HM, Aoun R, Koussa S, Taher AT. Effect of Deferasirox Use on the Educational Status of Patients with Thalassemia: A 20-Year, Single-Center Experience. 2nd MEGMA Conference on Thalassaemia and Other Haemoglobinopathies, Thalassemia International Federation (TIF) – Amman, Jordan – November 11th-12th 2016.
16. **Bou Fakhredin R\***, Moukhadder HM, Roumi J, Aoun R, Abou Nasr T, Taher AT. Prenatal Genetic Implantation as a Possible Alternative to Elective Abortion: The Lebanese Experience. 2nd MEGMA Conference on Thalassaemia and Other Haemoglobinopathies, Thalassemia International Federation (TIF) – Amman, Jordan – November 11th-12th 2016.
17. Abi Saad M, Moukhadder HM, Aoun R, Roumi J, **Bou Fakhredin R**, Aoun S, Taher AT. Impact of Prenatal Diagnosis of Thalassemia on Disease Prevention: A Single-Center Experience From Lebanon. 2nd MEGMA Conference on Thalassaemia and Other Haemoglobinopathies, Thalassemia International Federation (TIF) – Amman, Jordan – November 11th-12th 2016.
18. Roumi J, Moukhadder HM, **Bou Fakhredin R**, Aoun R, Taher AT. Insight into the Incidence and Inheritance Pattern of Beta-Thalassemia in Lebanon. 2nd MEGMA Conference on Thalassaemia and Other Haemoglobinopathies, Thalassemia International Federation (TIF) – Amman, Jordan – November 11th-12th 2016.
19. Saade C, **Bou Fakhredin R**, Al-Ashkar B, El-Merhi F. Current and state of the art imaging in multiple sclerosis: lesion characteristics and enhancement patterns during MRI. 101st Radiological Society of North America (RSNA) Scientific Assembly and Annual Meeting – Chicago, IL-November 29th – December 4th 2015.
20. Saade C, Al Fout G, Dorkmark B, El-Merhi F, Almohiy H, El-Achkar B, **Bou Fakhredin R**. Pharmacokinetic, Gadolinium and Technical Parameters Affecting Bolus Geometry during Contrast Enhanced Renal MR Angiography: An Overview. 101st Radiological Society of North America (RSNA) Scientific Assembly and Annual Meeting – Chicago, IL-November 29th – December 4th 2015.

\* Presenting Author

## ALTRE INFORMAZIONI

### University Appointments:

- Elected as the PhD Representative of 37<sup>th</sup> cycle students in the Translational Medicine Program at the University of Milan (Term 2021-2024)
- Elected as the PhD representative of the whole Translational Medicine Program at the level of the PhD Council at the University of Milan (Term 2021-2024)
- Elected as PhD representative in the student committee of the 4EU+ (European University) Alliance (2022-2024)

**Research skills:**

- Molecular techniques: DNA/RNA/protein extraction, western blots, IHC, cDNA synthesis, rt-PCR, ELISA, NADPH oxidase assay.
- In vivo: injections (IV/IP/IM/SC), breeding, handling, genotyping.
- How to write a Manuscript, Basic Computer searching, Building Search strategies in Pubmed, How to handle authorship, How to identify & submit to a journal, How to survive peer review

**Professional Memberships**

- European Hematology Association (EHA)
- European Hematology Association -Scientific Working Group (EHA-SWG) on Red Cells and Iron
- Sigma Xi-The Scientific Research Honor Society

Le dichiarazioni rese nel presente curriculum sono da ritenersi rilasciate ai sensi degli artt. 46 e 47 del DPR n. 445/2000.

Il presente curriculum, non contiene dati sensibili e dati giudiziari di cui all'art. 4, comma 1, lettere d) ed e) del D.Lgs. 30.6.2003 n. 196.

**RICORDIAMO** che i curricula **SARANNO RESI PUBBLICI sul sito di Ateneo** e pertanto si prega di non inserire dati sensibili e personali. Il presente modello è già precostruito per soddisfare la necessità di pubblicazione senza dati sensibili.

Si prega pertanto di **NON FIRMARE** il presente modello.

Luogo e data: Milano, 19/11/2024